The answer came from a pioneering study from our lab where we showed that the expression of the mature neuronal marker, high molecular weight microtubule-associated protein (MAP) isoforms MAP2 a and b was severely reduced in AD patients in the DG (1%) as determined by immunohistochemistry and in situ hybridization. Here, MAP2 is linked to Alzheimer disease.